Researchers of the Dept. of Neurochemistry and Neuropharmacology of the IIBB have just published a commentary in the journal Nature Reviews Drug Discovery (1ª of the field of the Pharmacology, IF = 47.1) on the project NEWMEDS (Novel Methods leading to New Medications in Depression and Schizophrenia) of the EU IMI call (Innovative Medicines Initiative) in which they participated between 2009 and 2015. Project partners included 7 leading EU academic institutions, 2 biotechnology companies and 12 multinational pharmaceutical companies and was coordinated by Shitij Kapur (King's College, London) and Tine Bryan Stensbol (Lundbeck, Copenhagen), with the group PI (Dr. Francesc Artigas) as academic leader of one of the workpackages (WP1). The comment in Nature Reviews Drug Discovery summarizes the scientific successes achieved in the project, as well as the excellent scientific collaboration achieved for the first time between traditionally antagonistic sectors (multinational pharmaceutical companies) and between them and academic groups. Since this is a key objective of the IMI call, NEWMEDS has become an example to be followed by other projects of this EU call.